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siddle  East  Respiratory  Syndrome  Coronavirus
MERS-CoV)  was  identiﬁed  in  Saudi  Arabia  in  2012.
ore than  1600  cases  in  26  countries  have  been
eported to  date  [1]. Many  patients  become  crit-
cally  ill,  with  a  reported  mortality  of up  to
0% among  MERS  CoV  patients  who  require  inten-
ive care  admission  [2].  Hospital-based  outbreaks
ave occurred  mainly  in  the  KSA.  Outside  of  the
SA, South  Korea  experienced  the  second  largest
escribed outbreak.  The  outbreak,  which  origi-
ated  from  a  single  index  case  who  had  a  history  of
ravel to  the  Middle  East,  spread  to  several  acute
are facilities  [3,4]. More  recently,  King  Abdulaziz
edical City,  Riyadh,  Saudi  Arabia,  experienced  a
igniﬁcant outbreak  that  led  to  the  closure  of  the
ne of  the  largest  tertiary  care  hospitals  in  the
ountry,  depriving  thousands  of  patients  of  routine
ealthcare  [5].
The  continued  threat  and  high  mortality  of  MERS
equire continued  collaborative  research  on  the
revention  and  treatment  of  this  disease.  The
ajority  of  the  burden  of  MERS  is  seen  in  Saudi
rabia. Hence,  the  Kingdom  has  led  the  design  and
onduct of  national  and  international  collaborative
esearch for  MERS,  with  the  goal  of  identifying
ffective therapies  that  will  beneﬁt  patients  across
he world.  In  the  spirit  of  achieving  these  goals,  the
ing Saud  Bin  Abdulaziz  University  for  Health  Sci-
nces and  the  King  Abdullah  International  Medical
c
r
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ttp://dx.doi.org/10.1016/j.jiph.2016.03.005
876-0341/© 2016 King Saud Bin Abdulaziz University for Health Scieesearch  Center  arranged  the  MERS  research  ini-
iative workshop,  which  took  place  on  September
—10, 2015  in  Riyadh,  KSA.  This  workshop  was  in
ollaboration  with  the  Ministry  of  National  Guard
ealth  Affairs,  the  Ministry  of  Health,  the  Saudi
ood and  Drug  Authority  and  with  national  and
nternational  experts  [6].
The meeting  included  a  pre-conference  solicita-
ion of topics  to  be  included  and  experts  to  attend,
ithout  distinction  between  governmental  or  non-
overnmental,  organizational,  academic,  private  or
ndustry-afﬁliation  participation.  Identiﬁed  individ-
als and  organizations  were  invited  to  attend  an
pen meeting  in  the  spirit  of  broad  collaboration
o review  the  current  state  of  knowledge,  to  iden-
ify gaps,  and  to  identify  the  most  promising  and
mportant  research  priorities  to  improve  the  care
nd outcomes  of  patients  with  MERS  and  to  more
roadly limit  the  impact  of  MERS  on  the  population.
The two-day  meeting  was  organized  into  three
aily moderated  sessions  consisting  of  20-min  pre-
entations by  experts,  followed  by  questions  and
 discussion  of  basic  and  translational  sciences,
iagnostics, epidemiology,  infection  prevention  and
ontrol, drug  and  biologic  therapeutics,  research
tudy design,  funding  opportunities,  and  regulatory
onsiderations  (Table  1). Industry  and  academic
epresentatives who  submitted  proposals  for  spe-
iﬁc potential  therapeutics  were  invited  to  present
nces. Published by Elsevier Limited. All rights reserved.
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Table  1  Topics  covered  in  the  MERS-CoV  research
initiative  workshop,  September  9—10,  2015;  King
Saud  Bin  Abdulaziz  University  for  Health  Sciences,
King  Abdulla  International  Medical  Research  Center,
Riyadh,  KSA.
Current  global  status  of  MERS
MERS  in  Saudi  Arabia  —  an  epidemiological  update
BARDA’S  approach  to  MERS  and  the  drug  development
for  emerging  infectious  diseases
The  virology  and  pathophysiology  of  MERS
A  holistic  approach  to  MERS
Immuno-therapeutic  options:  an  overview
WHO  guidance  on  convalescent  plasma  treatment
Convalescent  plasma  in  MERS
Novel  therapeutics  for  MERS  —  a  status  update  on
drug  development
An  overview  of  the  CSIRO  Australian  Animal  Health
Laboratory
Preventing  MERS:  critical  issues  and  gaps  in  research
Consideration  of  clinical  trials  during  outbreaks
Passive  immunity  for  emerging  and  re-emerging  high
consequence  viruses
Presentation,  clinical  course,  and  outcomes
Laboratory  testing  for  MERS
Serologic  assays
Epidemiological  studies  to  evaluate  transmission  or
studies  on  viral  shedding
Saudi  regulations  for  phase  I/II  I  clinical  studies
Potential  trial  designs  (target  populations,  blinding,
inclusion/exclusion  criteria,  and  prioritization  of
interventions)
Regulatory  issues  of  the  US  FDA
BARDA, Biomedical Advanced Research and Development
Authority; WHO, World Health Organization; CSIRO, Com-
monwealth Scientiﬁc and Industrial Research Organization;
USFDA, United States Food and Drug Administration.
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[7] Arabi YM, Fowler R, Bright RA, et al. Knowledge gapsprivileged  or  proprietary  information  in  a closed
session to  help  inform  attendees  of  promising  and
potential  therapeutics  to  consider  evaluating  in
clinical trials.
Both published  and  unpublished  sources  at
the workshop  identiﬁed  knowledge  gaps  in  the
therapeutic  and  non-therapeutic  aspects  of  MERS
research  [7].  Articles  on  selected  topics  that  were
presented  at  the  workshop  are  included  in  this
issue  of  the  Journal  of  Infection  and  Public  Health.
Articles  include  a  high-level  perspective  on  the  cur-
rent status  of  drug  development  and  clinical  trials
on MERS  therapies  and  a  description  of  the  clin-
ical spectrum  of  the  presentation  of  MERS,  both
of which  are  critical  for  the  design  of  clinical  tri-
als. In  addition,  an  overview  of  drug  development
and necessary  facilities  is presented  from  the  per-
spective  of  national  animal  and  basic  science  heath
laboratories.  Finally,  selected  promising  productsEditorial
re  explored,  including  LCA60  —  human-derived
onoclonal  antibodies,  nitazoxanide,  and  BCX4430
 a broad-spectrum  antiviral  adenosine  nucleoside
nalog; we  acknowledge  that  other  therapeutics
re at  various  stages  of  development  and  that
ew and  emerging  data  require  a  continual  re-
valuation  of  therapies  with  the  most  promise  for
valuation.  The  intent  of  this  workshop  and  the
ccompanying  proceedings  are  to  enhance  the  shar-
ng of  rapidly  evolving  basic  and  clinical  sciences
nd a multidisciplinary  early  peer  discussion  and
eview and  to  suggest  priorities  for  ongoing  MERS
herapeutic  research.
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